P-60 哥伦比亚波哥大的纤维扫描肝病诊断性能

IF 3.7 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Annals of hepatology Pub Date : 2024-02-01 DOI:10.1016/j.aohep.2023.101247
Diana Del Pilar Torres , Benedicto Velasco , Jonathan Alexander Guezguan
{"title":"P-60 哥伦比亚波哥大的纤维扫描肝病诊断性能","authors":"Diana Del Pilar Torres ,&nbsp;Benedicto Velasco ,&nbsp;Jonathan Alexander Guezguan","doi":"10.1016/j.aohep.2023.101247","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and Objectives</h3><p>In the diagnostic process of liver diseases the clinical history and hepatic biochemical profile are fundamental. Liver biopsy is the gold standard for diagnosis, evaluation of activity, fibrosis status or therapeutic response. It is an invasive procedure with risk of complications. With respect to fibrosis staging, a key point in decision making in follow-up and treatment, non-invasive tests have been developed that are easily accessible and without resorting to biopsy. The calculation of the FIB-4 and APRI indices is useful in general practice, but not sufficient to determine the degree of fibrosis in early and intermediate stages. Liver fibrosis increases stiffness and decreases tissue elasticity and can be assessed by Elastography, this technique is sensitive to differentiate patients without fibrosis from those with advanced fibrosis, in a fast and well tolerated way. This study aims to describe the diagnostic performance for detecting liver fibrosis of FibroScan compared with APRI and FIB4 indices versus liver biopsy in patients with liver disease in Bogota.</p></div><div><h3>Materials and Methods</h3><p>Retrospective cohort study, cross-sectional, consecutive sampling, performed in the period 2019-2022, the APRI, FIB4 and Fibroscan indices were compared with the biopsy result, the diagnostic accuracy measures for APRI, FIB4 and FibroScan were described and an area under the curve analysis (ACOR) was performed.</p></div><div><h3>Results</h3><p>Biopsy was positive for fibrosis in 40%, FibroScan showed excellent performance for detecting fibrosis, with an ACOR of 0.90 (CI: 0.83 - 0.97), APRI indices of 0.52 (CI: 0.35- 0.68) and FIB4 of 0.52 (CI:0.37 - 0.68).</p></div><div><h3>Conclusions</h3><p>FibroScan is a useful tool for the diagnosis and follow-up of chronic liver disease, it should be used in combination with other diagnostic tests and clinical evaluation. FibroScan showed excellent performance in discriminating patients with liver fibrosis compared to APRI and FIB4 indices and is better at detecting advanced stages.</p></div>","PeriodicalId":7979,"journal":{"name":"Annals of hepatology","volume":null,"pages":null},"PeriodicalIF":3.7000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1665268123003502/pdfft?md5=d394d7b70ce18f88d7b19745e0d9a116&pid=1-s2.0-S1665268123003502-main.pdf","citationCount":"0","resultStr":"{\"title\":\"P-60 DIAGNOSTIC PERFORMANCE OF FIBROSCAN FOR LIVER DISEASE IN BOGOTA, COLOMBIA\",\"authors\":\"Diana Del Pilar Torres ,&nbsp;Benedicto Velasco ,&nbsp;Jonathan Alexander Guezguan\",\"doi\":\"10.1016/j.aohep.2023.101247\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction and Objectives</h3><p>In the diagnostic process of liver diseases the clinical history and hepatic biochemical profile are fundamental. Liver biopsy is the gold standard for diagnosis, evaluation of activity, fibrosis status or therapeutic response. It is an invasive procedure with risk of complications. With respect to fibrosis staging, a key point in decision making in follow-up and treatment, non-invasive tests have been developed that are easily accessible and without resorting to biopsy. The calculation of the FIB-4 and APRI indices is useful in general practice, but not sufficient to determine the degree of fibrosis in early and intermediate stages. Liver fibrosis increases stiffness and decreases tissue elasticity and can be assessed by Elastography, this technique is sensitive to differentiate patients without fibrosis from those with advanced fibrosis, in a fast and well tolerated way. This study aims to describe the diagnostic performance for detecting liver fibrosis of FibroScan compared with APRI and FIB4 indices versus liver biopsy in patients with liver disease in Bogota.</p></div><div><h3>Materials and Methods</h3><p>Retrospective cohort study, cross-sectional, consecutive sampling, performed in the period 2019-2022, the APRI, FIB4 and Fibroscan indices were compared with the biopsy result, the diagnostic accuracy measures for APRI, FIB4 and FibroScan were described and an area under the curve analysis (ACOR) was performed.</p></div><div><h3>Results</h3><p>Biopsy was positive for fibrosis in 40%, FibroScan showed excellent performance for detecting fibrosis, with an ACOR of 0.90 (CI: 0.83 - 0.97), APRI indices of 0.52 (CI: 0.35- 0.68) and FIB4 of 0.52 (CI:0.37 - 0.68).</p></div><div><h3>Conclusions</h3><p>FibroScan is a useful tool for the diagnosis and follow-up of chronic liver disease, it should be used in combination with other diagnostic tests and clinical evaluation. FibroScan showed excellent performance in discriminating patients with liver fibrosis compared to APRI and FIB4 indices and is better at detecting advanced stages.</p></div>\",\"PeriodicalId\":7979,\"journal\":{\"name\":\"Annals of hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1665268123003502/pdfft?md5=d394d7b70ce18f88d7b19745e0d9a116&pid=1-s2.0-S1665268123003502-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1665268123003502\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hepatology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1665268123003502","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介和目标 在肝病诊断过程中,临床病史和肝脏生化指标是基础。肝活检是诊断、评估肝脏活动、肝纤维化状态或治疗反应的金标准。这是一种侵入性手术,存在并发症风险。肝纤维化分期是随访和治疗决策的关键点,目前已开发出无需活检、方便使用的非侵入性检测方法。FIB-4 和 APRI 指数的计算在一般实践中很有用,但不足以确定早期和中期肝纤维化的程度。肝纤维化会增加组织的硬度,降低组织的弹性,可以通过弹性成像技术进行评估,该技术能以快速、耐受性好的方式灵敏地区分无肝纤维化患者和肝纤维化晚期患者。本研究旨在描述在波哥大的肝病患者中,FibroScan 与 APRI 和 FIB4 指数与肝活检相比,在检测肝纤维化方面的诊断性能。材料与方法回顾性队列研究,横断面,连续取样,在 2019-2022 年期间进行,将 APRI、FIB4 和 Fibroscan 指数与活检结果进行比较,描述 APRI、FIB4 和 FibroScan 的诊断准确性指标,并进行曲线下面积分析(ACOR)。结论纤维扫描是诊断和随访慢性肝病的有用工具,应与其他诊断测试和临床评估结合使用。与 APRI 和 FIB4 指数相比,纤维扫描在鉴别肝纤维化患者方面表现出色,在检测晚期肝纤维化方面也更胜一筹。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
P-60 DIAGNOSTIC PERFORMANCE OF FIBROSCAN FOR LIVER DISEASE IN BOGOTA, COLOMBIA

Introduction and Objectives

In the diagnostic process of liver diseases the clinical history and hepatic biochemical profile are fundamental. Liver biopsy is the gold standard for diagnosis, evaluation of activity, fibrosis status or therapeutic response. It is an invasive procedure with risk of complications. With respect to fibrosis staging, a key point in decision making in follow-up and treatment, non-invasive tests have been developed that are easily accessible and without resorting to biopsy. The calculation of the FIB-4 and APRI indices is useful in general practice, but not sufficient to determine the degree of fibrosis in early and intermediate stages. Liver fibrosis increases stiffness and decreases tissue elasticity and can be assessed by Elastography, this technique is sensitive to differentiate patients without fibrosis from those with advanced fibrosis, in a fast and well tolerated way. This study aims to describe the diagnostic performance for detecting liver fibrosis of FibroScan compared with APRI and FIB4 indices versus liver biopsy in patients with liver disease in Bogota.

Materials and Methods

Retrospective cohort study, cross-sectional, consecutive sampling, performed in the period 2019-2022, the APRI, FIB4 and Fibroscan indices were compared with the biopsy result, the diagnostic accuracy measures for APRI, FIB4 and FibroScan were described and an area under the curve analysis (ACOR) was performed.

Results

Biopsy was positive for fibrosis in 40%, FibroScan showed excellent performance for detecting fibrosis, with an ACOR of 0.90 (CI: 0.83 - 0.97), APRI indices of 0.52 (CI: 0.35- 0.68) and FIB4 of 0.52 (CI:0.37 - 0.68).

Conclusions

FibroScan is a useful tool for the diagnosis and follow-up of chronic liver disease, it should be used in combination with other diagnostic tests and clinical evaluation. FibroScan showed excellent performance in discriminating patients with liver fibrosis compared to APRI and FIB4 indices and is better at detecting advanced stages.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of hepatology
Annals of hepatology 医学-胃肠肝病学
CiteScore
7.90
自引率
2.60%
发文量
183
审稿时长
4-8 weeks
期刊介绍: Annals of Hepatology publishes original research on the biology and diseases of the liver in both humans and experimental models. Contributions may be submitted as regular articles. The journal also publishes concise reviews of both basic and clinical topics.
期刊最新文献
Editorial board Alcohol-related liver disease: A global perspective Hepatitis B virus X protein differentially regulates the angiogenesis of Hepatocellular Carcinoma through p53-VEGF axis according to glucose levels Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1